Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma

Launched by COLUMBIA UNIVERSITY · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how additional MRI scans can improve radiation treatment for patients with high-grade gliomas, which are aggressive types of brain tumors like glioblastoma and anaplastic astrocytoma. Researchers want to see if taking these scans weekly during radiation therapy helps doctors better target the tumor and provide more effective treatment.

To join the study, participants need to be at least 18 years old and have a confirmed diagnosis of one of the targeted brain tumors. They should also be healthy enough to undergo treatment, as indicated by a performance status score of 70 or higher. Candidates must be planning to receive a specific amount of radiation, and women who can become pregnant need to have a negative pregnancy test before starting. Those who qualify will undergo MRI scans during their treatment, which helps monitor the tumor's response and adjust the therapy if needed. This study is currently recruiting participants, and it's an opportunity to contribute to important research that could lead to better outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma
• • History and physical examination within 28 days prior to enrollment
• • Karnofsky performance status 70 or greater
• • Age 18 years or greater
• • Negative pregnancy test for females of childbearing potential before 1st research MRI, performed in accordance to institutional guidelines.
• • Plan to receive 59.4-60 Gy in 30-33 fractions of radiotherapy. Glioblastoma patients over 65 year-old can receive hypofractionated radiotherapy including 40 Gy in 15 fractions.
• Exclusion Criteria:
• • Prior therapy for tumor except for biopsy or resection, including prior radiotherapy to the brain.
• • Clinical or radiological evidence of metastatic disease outside the brain
• • Prior malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years